Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancerLan Shen, Xiaomin Niu, Hong Jian, et al.
Therapeutic Advances in Medical Oncology|March 10, 2023
Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLCWendi Xuzhang, Huayan Huang, Yongfeng Yu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|May 23, 2012
[Efficacy of gemcitabine and vinorelbine in first-line treatment with advanced non-small cell lung cancer: a multicentre retrospective study]Yongfeng Yu, Li Zhang, Zhisheng Ren, et al.
Cancer Medicine|March 14, 2020
First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancerLan Shen, Tan Qiang, Ziming Li, et al.
Advances in Therapy|March 17, 2021
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World EvidenceShun Lu, Jin-Yuan Shih, Tae-Won Jang, et al.
Microorganisms|December 23, 2022
Antimicrobial Resistance Surveillance of Tigecycline-Resistant Strains Isolated from Herbivores in Northwest ChinaYongfeng Yu, Changchun Shao, Xiaowei Gong, et al.
Oncogene|September 8, 2020
Correction: FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancerKaixuan Wang, Wenxiang Ji, Yongfeng Yu, et al.
Cell Biochemistry and Function|June 3, 2010
Functional roles of PC-PLC and Cdc20 in the cell cycle, proliferation, and apoptosisZhiwei Chen, Yongfeng Yu, Da Fu, et al.
BMC Pulmonary Medicine|July 3, 2025
An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancerYongfeng Yu, Fei Yao, Jin Wang, et al.
Journal of Translational Medicine|July 14, 2024
EGFR mutations induce the suppression of CD8<sup>+</sup> T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancerHuayan Huang, Xiaokuan Zhu, Yongfeng Yu, et al.
Pageof 9